OKYO Pharma Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by OKYO Pharma Ltd on September 5, 2024. The filing serves to disclose a specific transaction involving the company's Executive Chairman, Gabriele Cerrone, rather than reporting on a standard financial quarter or fiscal year.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a share purchase transaction.
- Transaction Price: US$1.15 per share.
- Shares Purchased: 80,000 ordinary shares.
- Market: NASDAQ.
Material Changes
The primary material change disclosed is an increase in the beneficial ownership of the Executive Chairman. Panetta Partners Limited, an entity in which Gabriele Cerrone holds a beneficial interest, purchased 80,000 shares. This transaction increased Mr. Cerrone's total shareholding to 9,801,570 shares, representing 28.97% of the company's issued share capital.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding business outlook, financial guidance, or operational risks. It strictly reports the share acquisition and notes that the attached news announcement (Exhibit 99.1) is furnished but not deemed "filed" for liability purposes under Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the current total issued share capital to confirm the 28.97% ownership calculation.
- Review the attached Exhibit 99.1 (News Announcement) for any additional context regarding the purchase.
- Check recent trading volumes on NASDAQ to assess the impact of this transaction on market liquidity.
- Confirm if this purchase triggers any additional reporting thresholds under UK or US securities regulations.